Table 3.
Comparison of SCA cases with and without MVP*
| MVP (n=17) | No MVP (n=712) | p value | |
|---|---|---|---|
| Age | 60.9 ± 16.4 | 69.7 ± 14.7 | 0.02 |
| Male | 12 (70.6) | 459 (64.5) | 0.60 |
| White | 14 (82.4) | 599 (84.7) | 0.73 |
| Body Mass Index | 27.0 ± 5.8 | 30.3 ± 9.1 | 0.18 |
| Hypertension | 7 (41.2) | 561 (78.9) | 0.001 |
| Diabetes | 1 (5.9) | 330 (46.4) | 0.001 |
| Known CAD | 5 (29.4) | 467 (65.6) | <0.0001 |
| Chronic Kidney disease | 2 (11.8) | 250 (35.2) | 0.04 |
| LVEF | 54.2 ± 14.7 | 48.1 ± 16.9 | 0.14 |
| LVEF ≤ 35% | 1 (6.7) | 196 (28.5) | 0.08 |
| Left atrial diameter (mm) | 45.0 ± 8.7 | 44.9 ± 10.1 | 0.98 |
| LV Diameter (mm) | 54.7 ± 7.3 | 51.8 ± 10.6 | 0.38 |
| Moderate or severe MR | 10 (58.8) | 170 (23.9) | 0.02 |
| Beta Blockers | 9 (52.9) | 404 (59.0) | 0.62 |
| ACE Inhibitors | 4 (23.5) | 338 (49.3) | 0.05 |
| ARBs | 1 (5.9) | 65 (9.5) | 1.0 |
| Anti-arrhythmic drugs | 2 (11.7) | 219 (32.0) | 0.11 |
| Antiplatelets | 7 (41.2) | 510 (74.4) | 0.002 |
| Lipid lowering drugs | 2 (11.7) | 337 (49.2) | 0.002 |
| QT prolonging drugs | 5 (29.4) | 334 (48.7) | 0.11 |
| QTc | 429.3 ± 33.1 | 459.0 ± 40.6 | 0.35 |
*
Data presented as mean ± SD and as n (%).
SCA- Sudden cardiac arrest, MVP- Mitral valve prolapse, CAD- Coronary artery disease, LVEF- Left ventricular ejection fraction, LV- Left ventricle, MR-Mitral regurgitation, ACE-Angiotensin converting enzyme, ARB-Angiotensin receptor blocker, QTc- corrected QT interval QTc information available for 6 MVP cases and 285 non-MVP cases.
Information on medications was available for 685 non-MVP cases